Marinol - Dronabinol

Schedule II drugs include Marinol (dronabinol), a synthetic version of THC in pill form, which has a currently accepted medical use in the United States primarily to alleviate nausea and stimulate appetite in cancer patients. Although Marinol may be legally prescribed and has been available for several... 

Roxane Laboratories, Inc. Q A about therapy with Marinol (dronabinol). Pamphlet. Columbus, OH, 1997. 

Keywords forensics THC-A Cannabis Marinol Dronabinol metabolite derivatization negative chemical ionization... 

Dronabinol. Marinol ( ii7R-/n7 j )-6i7,7,8,I0i7-tetrahydro-6,6,9-trimethyl-3-pentyl-6JT-diben2o(B,D) pyran-I-ol is the principal psychoactive substance present in Cannabis sativa F., ie, marijuana. It is a controlled substance, formulated in sesame oil and encapsulated in soft gelatin capsules for oral adrninistration. 

Take granisetron (Kytril), dronabinol (Marinol), or ondansetron (Zofran) before antineoplastic chemodierapy (oral, intravenous) about 30 minutes before the chemodierapy treatment. Take dolasetron mesylate (Anzemet) orally at least 1 hour before... 

On the market are two drugs imder the trade names of Dronabinol, which is the generic name of trans-A9-THC, and Marinol, which is a medicine containing synthetic dronabinol in sesame oil for oral intake, distributed by Unimed Pharmaceuticals. 

Fig. 5) with olivetol (5.2) in the presence of boron trifluoride etherate, BF3 0C(C2H5)2 with CBD as a key intermediate. This one-step synthesis of A9-THC is also used for the production of synthetic dronabinol, which is used in the medicinal application named Marinol. The mechanism of this synthesis is particular described by Razdan et al. [71] and is shown in Fig. 5... 

So, the 20th century actually led to an almost total disappearance of C. sativa for medicinal purposes. The only source for THC, which became the focus of scientific research, was fhe rafher fedious exfracfion and purification from confiscated hashish or marihuana. In 1972 the first commercially viable total synthesis of A9-THC was established and it became the first cannabinoid available as a modern medicine in the form of soft gel capsules (the active ingredient being called dronabinol from tetrahydrocannabinol) under the trade name Marinol for the prevention of nausea and vomiting during cancer chemotherapy. 

Standardised preparations of cannabinoid agonists are available for therapeutic use in some countries [238]. Dronabinol (Marinol ), an oral preparation of A -THC (67), is used clinically as an appetite stimulant in AIDS patients and an antiemetic in cancer chemotherapy. A synthetic analogue of (67), nabilone (Cesamet ), (381), is also used to suppress nausea and vomiting in cancer chemotherapy. 

Much debate has been waged over medicinal uses of cannabis. Several therapeutic uses have been proposed, including antiemetic, analgesic, appetite stimulant, and muscle relaxant. A synthetic cannabinoid, dronabinol (Marinol) has been marketed for clinical treatment of appetite loss, nausea, and vomiting. Although synthetic, it is identical to the main psychoactive chemical constituent of cannabis (A9-THC). 

Calhoun SR, Galloway GP, Smith DE. (1998). Abuse potential of dronabinol (Marinol). J Psychoactive Drugs. 30(2) 187-96. 

Medical marijuana remains a controversial topic, but synthetic THC, dronabinol, marketed under the trade name Marinol, has been available by prescription since 1986. The dronabinol analog nabilone is another THC prescription drug marketed under the name Cesamet. Marinol and Cesamet, taken as capsules, have Food Drug Administration approval as an antinausea agent and appetite stimulant (for AIDS patients), but they are also prescribed for depression and muscle spasms. In 2005, Canada was the first country to approve Sativex, a cannabis spray that relieves pain in people with multiple sclerosis. 

Oral preparations of A9-THC (dronabinol, marinol) and the synthetic structural analog nabilone are marketed as suppressants of nausea and vomiting provoked by antitumor agents. Furthermore A9-THC is employed to stimulate the appetite of AIDS patients. 

A9-THC is marketed as marinol or dronabinol for the treatment of chemotherapy-induced nausea and vomiting in Australia, Canada, Israel, South Africa and the USA. It was granted orphan drug status in the US for the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of AIDS. A9-THC is in phase I trials for spasticity, multiple sclerosis and postoperative pain. Several small clinical studies have confirmed the effectiveness of A9-THC as an analgesic, with doses of 15 to 20 mg being comparable to 60 to 120 mg of codeine (Williamson and Evans, 2000). 

Aprepitant (Emend) Chlorpromazine (Thorazine) Dimenhydrinate (Dramamine, others) Dolasetron (Anzemet) Dronabinol (Marinol) Droperidol (Inapsine) Granisetron (Kytril)... 

Dronabinol (A9-tetrahydrocannabinol THC Marinol) is FDA approved for treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetics. With mildly or moderately emetogenic chemotherapy, it is more effective than placebo and equivalent or superior to oral prochlorperazine. Dry mouth, sedation, orthostatic hypotension, ataxia, dizziness, and dysphoria occur frequently, particularly in middle-aged and older patients. 

FDA approves synthetic THC, or dronabinol (Marinol) as an anti-emetic for cancer patients undergoing chemotherapy. 

Dronabinol. Dronabinol is a synthetic form of THC that was approved for medical use by the FDA in 1985. Sold under the trade name Marinol, it is prescribed as an antiemitic for cancer patients undergoing chemotherapy and as an appetite stimulant for AIDS patients who become anorexic. Marinol is manufactured in 2.5-, 5-, and 10-mg capsules, which are taken orally. Critics argue that suppositories would be more useful than capsules since cancer and AIDS patients are often unable to keep food down. 

---